DND - Wow you're just a ball of optimism. I would think that anyone who questions the outcome of the primary target at this time should reduce or eliminate their position. You are very correct that there were certain misses in the past that caused long faces. There is also no question that our share price will be devistated if we miss the primary this go round as well. The amount of effort by the company over the last year to point attention to the secondary indications to me is speaking volumes. The primary is a black and white statement. We either have it statistically or we don't. If we don't it's recapitalization time, likely with a significant share consolidation. Being that I'm still in this story after 12 years or so I obviously believe there will be success. If your conviction of the trials outcome is low or non existent, strongly consider all of your options. As kelsee said to icon, go invest in a wheelbarrow. If your conviction is not that strong, a change purse may be more than you ( or me ) will need.

The secondary's, specifically dementia where their has been virtually no success in the whole biotech industry is the most curious. I ask myself every day, sometimes a couple of times a day; what have they seen from the data that they do get to make them want to crow about this? If there was any question about whether or not they had something worth talking about, silence would be the best approach. If there wasn't anything worth talking about it wouldn't be missed. Their approach is exactly opposite. What do they know or think they know? The CKD stage was set in the post hoc follow up from ASSURE. Again what are they seeing from the data that they do get to have them crowing about this for the last 18 months?

I would agree with your view if they had just started talking about these secondary's but this has been going on now for 12 and 18 months.

I hope we need that wheelbarrow...my change purse has a hole in it.

tada